Renal Cell Carcinoma clinical trials

Explore recruiting renal cell carcinoma clinical trials.

Recruiting renal cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Renal Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study

France

Therapeutic use (Phase IV) EU CTIS Study details

CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)

Italy, Spain, Hungary, Poland, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)

Hungary, Finland, Sweden, Netherlands, Ireland, Spain +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Renal Cell Carcinoma trials by city

Renal Cell Carcinoma in Toronto Renal Cell Carcinoma in Vancouver Renal Cell Carcinoma in Montreal Renal Cell Carcinoma in Calgary Renal Cell Carcinoma in Edmonton Renal Cell Carcinoma in Ottawa Renal Cell Carcinoma in Winnipeg Renal Cell Carcinoma in Quebec City Renal Cell Carcinoma in Hamilton Renal Cell Carcinoma in Kitchener Renal Cell Carcinoma in London Renal Cell Carcinoma in Halifax Renal Cell Carcinoma in New York Renal Cell Carcinoma in Los Angeles Renal Cell Carcinoma in Chicago Renal Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease